CAMBRIDGE, Mass., Aug. 25, 2022 -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced...
Biovitrum and Syntonix set to begin Phase 1/2a clinical trial for the treatment of Hemophilia B
News | 03. 04. 2008
Biovitrum AB (publ), Sweden, and Syntonix Pharmaceuticals, Inc., USA, have obtained approval from the US Food and Drug Administration to commence a clinical phase I/IIa study of a long-acting, recombinant Factor IXFc for the treatment of Hemophilia B.